Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Immunotherapy is the new promise in effectively combating cancer. It has proven to be effective in solid tumors of an inflamed phenotype but still faces challenges, especially in tumor lesions that are less invaded by immune cells. Cancer stem/initiating cells (CSCs) are defined as tumor cells that have the principal properties of self-renewal, clonal tumor initiation capacity, and clonal long-term repopulation potential. CSCs reside in niches, which may be anatomically distinct regions within the tumor microenvironment. These niches maintain the principle properties of CSCs, preserve their phenotypic plasticity, protect them from the immune system, and facilitate their metastatic potential. According to the CSC paradigm, only complete eradication of these CSCs will prevent cancer from recurring. By combining methods of mouse genetics, 3D primary organotypic cultures, biomedical live imaging and high throughput analyses on the single cell level, my research aims at understanding how immune cells and cancer stem cells interact within the niche during breast cancer evolution and metastasis. Subsequently, my team will explore ways by which engineering the CSC niche will render it more susceptible to immunotherapy.
